Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 12/20 | 0.40 |
| ▸ | NMT2 | O60551 | 11/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CBX7 | O95931 | 1/20 | 0.36 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.36 |
| ▸ | CBX8 | Q9HC52 | 1/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18760191 | 0.94 | NMT1 (0.44) | NMT1NMT2EPHX1 | |
| SCHEMBL18786235 | 0.94 | EPHX1 (0.40) | NMT1NMT2EPHX1 | |
| SCHEMBL18760195 | 0.93 | EPHX1 (0.42) | NMT1NMT2EPHX1 | |
| SCHEMBL18785521 | 0.91 | NMT1 (0.37) | NMT1NMT2OPRM1OPRD1CBX7 | |
| SCHEMBL20633489 | 0.90 | NMT1 (0.41) | NMT1NMT2OPRM1OPRD1QRFPR | |
| SCHEMBL18760192 | 0.90 | NMT1 (0.46) | NMT1NMT2 | |
| SCHEMBL23840017 | 0.90 | NMT1 (0.46) | NMT1NMT2 | |
| SCHEMBL20633846 | 0.88 | NMT1 (0.48) | NMT1NMT2 | |
| SCHEMBL23840151 | 0.88 | NMT1 (0.46) | NMT1NMT2 | |
| SCHEMBL20634649 | 0.88 | NMT1 (0.48) | NMT1NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290726-A1 | BIOCONJUGATES WITH CHEMICALLY MODIFIED BACKBONES | SYMIC HOLDINGS, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290726-A1 | BIOCONJUGATES WITH CHEMICALLY MODIFIED BACKBONES | COL14A1, COLGALT1, PTMS | NMT1 331/4885NMT2 414/4885OPRM1 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.